Xiaobin Mei
Impact in
- Nephrology top 5%
- Chronic Kidney Disease and Diabetes
- Gout, Hyperuricemia, Uric Acid
- Clinical Biochemistry top 10%
- Advanced Glycation End Products research
Papers in
-
- Inflammasome and immune disorders 5
- Heme Oxygenase-1 and Carbon Monoxide 2
- Peroxisome Proliferator-Activated Receptors 2
-
- IL-33, ST2, and ILC Pathways 3
- Psoriasis: Treatment and Pathogenesis 2
- Co-authors
- Jiajun Fan (13 shared papers)Dianwen Ju (11 shared papers)Jingyun Luan (7 shared papers)Xuyao Zhang (6 shared papers)Wei Chen (6 shared papers)Tao Ding (4 shared papers)Qi Bian (6 shared papers)Shaofei Wang (4 shared papers)
- Journals
- Applied Microbiology and Biotechnology (3 papers)Frontiers in Immunology (2 papers)Tumor Biology (2 papers)Cell Death Discovery (1 paper)Acta Pharmaceutica Sinica B (1 paper)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Xiaobin Mei
21 papers receiving 632 citations
Peers
Comparison fields: 5 of 85
- Nephrology 120
- Clinical Biochemistry 54
- Immunology 152
- Pharmacology 51
- Molecular Biology 278
Countries citing papers authored by Xiaobin Mei
This map shows the geographic impact of Xiaobin Mei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobin Mei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobin Mei more than expected).
Fields of papers citing papers by Xiaobin Mei
This network shows the impact of papers produced by Xiaobin Mei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobin Mei. The network helps show where Xiaobin Mei may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaobin Mei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 160 | |
| 2 | 2017 | 85 | |
| 3 | 2019 | 82 | |
| 4 | 2019 | 48 | |
| 5 | 2020 | 44 | |
| 6 | 2013 | 29 | |
| 7 | 2021 | 28 | |
| 8 | 2020 | 27 | |
| 9 | 2017 | 25 | |
| 10 | 2019 | 23 | |
| 11 | 2015 | 19 | |
| 12 | 2023 | 16 | |
| 13 | 2015 | 10 | |
| 14 | 2014 | 9 | |
| 15 | 2021 | 8 | |
| 16 | 2022 | 7 | |
| 17 | 2023 | 4 | |
| 18 | 2004 | 4 | |
| 19 | Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis. | 2015 | 4 |
| 20 | 2022 | 2 |
About Xiaobin Mei
Xiaobin Mei is a scholar working on Molecular Biology, Immunology, Physiology, Nephrology and Genetics, having authored 22 papers that have together received 635 indexed citations. Recurring topics across this work include Inflammasome and immune disorders (5 papers), IL-33, ST2, and ILC Pathways (3 papers), Adipose Tissue and Metabolism (2 papers), Heme Oxygenase-1 and Carbon Monoxide (2 papers), Renal Diseases and Glomerulopathies (2 papers), Drug-Induced Hepatotoxicity and Protection (2 papers), Psoriasis: Treatment and Pathogenesis (2 papers) and Peroxisome Proliferator-Activated Receptors (2 papers). The work is most often cited by research in Nephrology (120 citations), Clinical Biochemistry (54 citations), Immunology (152 citations), Pharmacology (51 citations) and Molecular Biology (278 citations). Xiaobin Mei has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Jiajun Fan, Dianwen Ju, Jingyun Luan, Xuyao Zhang, Wei Chen, Tao Ding, Qi Bian, Shaofei Wang, Yilan Shen and Yubin Li. Their work appears in journals such as Applied Microbiology and Biotechnology, Frontiers in Immunology, Tumor Biology, Cell Death Discovery and Acta Pharmaceutica Sinica B.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.